A paramedic fills a syringe with a vaccine against the coronavirus disease (COVID-19) before administering it to a health worker during its trials at Civil Hospital in Ahmedabad BENGALURU (Reuters) ...

Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show ...

BENGALURU (Reuters) - Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at ...

New Delhi, May 10 (PTI) Zydus Cadila has received final approval from the US health regulator to market Carbidopa tablets, used for treating symptoms of Parkinson’s disease. Parkinson’s symptoms ...

Demand outpacing COVID-19 vaccine supplies has already been a problem for players with authorized products, including Pfizer and AstraZeneca. But an Indian drugmaker known for its generics is ...

Zydus Cadila has completed (PDF) a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company said the DNA vaccine ...

(Eds: Adding info) New Delhi, Aug 13 () Drug firm Zydus Cadila on Thursday said it has launched Remdesivir under the brand name Remdac, used for treating patients suffering from severe symptoms of ...

BENGALURU (Reuters) -Indian drugmaker Zydus Cadila said on Thursday it has applied for emergency use approval of its three-dose COVID-19 vaccine that showed efficacy of 66.6% in an interim study and ...

India's Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild COVID-19, as the country grapples with a shortage of medicines and vaccines needed to ...

Cadila Healthcare Ltd. (also known as Zydus Cadila) has received emergency use authorization (EUA) in India for Zycov-D, making it the world’s first plasmid DNA vaccine for COVID-19. Besides the adult ...